SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Nucl Med. 2008; 49 (Supplement 1):352P
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Yoshikawa, K.
Right arrow Articles by Suzuki, K.
PubMed
Right arrow Articles by Yoshikawa, K.
Right arrow Articles by Suzuki, K.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

Use of FDG-PET/CT to predict prognosis of patients with pancreas cancer treated by carbon ion radiotherapy

Kyosan Yoshikawa1, Mitsuhiko Hasebe1, Seiya Ohashi1, Sherif Abd-Elrazek1, Hiroyuki Ishikawa1, Katsumi Tamura1, Katsuyuki Tanimoto1, Susumu Kandatsu1, Tsuneo Saga1 and Kazutoshi Suzuki1

1 Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba-shi, Japan

1488

Objectives: We evaluated whether FDG uptake before carbon ion radiotherapy (CIRT) and its change after CIRT were the predictor of local recurrence, metastasis and survival in patients with pancreas cancer.

Methods: FDG-PET/CT was performed in 18 patients with pancreas cancer before CIRT, and 14 patients out of them were received FDG-PET/CT at one month after completion of CIRT. The average patient age was 64.4 years (range 48 to 77). Patients were followed for 3.5 to 38.4 months (mean 11.7 months) after CIRT. FDG uptake was measured semi-quantitatively using average SUV. The tumor SUV and change of SUV after CIRT were compared statistically with local recurrence rate, metastatic rate and result of prognosis by Kaplan-Meire analysis.

Results: Mean tumor SUV before and after CIRT was 6.4 and 4.7, respectively. SUV at one month after completion of CIRT seemed to be not enough reduced, but there was significant difference in tumor SUV between before CIRT and after CIRT (p=0.0036), Patients with baseline SUV ≥ 7.4 had significant higher local recurrence rate than patients with baseline SUV < 7.4 (p=0.0057). Patients with baseline SUV ≥ 9.2 had significant higher metastatic rate than patients with baseline SUV < 9.2 (p=0.0022). Patients with baseline SUV ≥ 9.2 had significant better prognosis than patients with baseline SUV < 9.2 (p=0.0053). SUV after CIRT and change of SUV between pre and post CIRT showed no statistical difference in any factors.

Conclusions: FDG uptake before CIRT was a successful predictor of local recurrence rate, metastatic rate and survival in patients with pancreas cancer treated by CIRT. It seemed to be somewhat too early to evaluate therapeutic effect at one month after CIRT.





Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Yoshikawa, K.
Right arrow Articles by Suzuki, K.
PubMed
Right arrow Articles by Yoshikawa, K.
Right arrow Articles by Suzuki, K.